Marc Banjak

General Counsel at DOVA PHARMACEUTICALS, INC.

Consumer Services

Health Technology

Profile

Marc A.
Banjak is currently the Secretary & General Counsel at iBio, Inc. and the General Counsel at Dova Pharmaceuticals, Inc. He previously worked as the General Counsel at Istari Oncology, Inc. Banjak received his undergraduate degree from Franklin & Marshall College, his graduate degree from the University of Denver, and his doctorate from Sturm College of Law.

Marc Banjak active positions

Companies	Position	Start
DOVA PHARMACEUTICALS, INC.	General Counsel	-
IBIO, INC.	General Counsel	-

All active positions of Marc Banjak

Former positions of Marc Banjak

Companies	Position	End
Istari Oncology, Inc. Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC.	Comptroller/Controller/Auditor	-

See the detail of Marc Banjak's experience

Training of Marc Banjak

Franklin & Marshall College	Undergraduate Degree
University of Denver	Graduate Degree
Sturm College of Law	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Marc Banjak's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
IBIO, INC.	Health Technology

Private companies	2
Dova Pharmaceuticals, Inc. Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC.	Health Technology
Istari Oncology, Inc. Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC.	Health Technology